Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
IPO Year:
Exchange: NASDAQ
Website: fennecpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/22/2022 | $9.00 → $12.00 | Neutral → Overweight | Cantor Fitzgerald |
| 9/7/2022 | $11.00 | Overweight | CapitalOne |
| 8/8/2022 | $14.00 | Buy | Craig Hallum |
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
3 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
3 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
3 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event. Conference Details: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton New York Times Square Hotel, New York City About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce t
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Thursday, November 7, 2024Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/e6my278s To access the conference call, please register using https://edge.media-server.com/mmc/p/e6m
~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that it has strengthened its executive leadership team with the appointments of Pierre S. Sayad, PhD, M.S., as chief medical officer, Terry Evans as chief commercial officer and Christiana Cioffi, MBA, as chief strategy officer, all of which become effective immediately. "Building an experienced, multi-talented executive leadership
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment ConferenceDate: September 11, 2024Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ETLocation: New York City, Lotte NY Palace Hotel, Holmes 1, 4th Floor Event: Cantor Fitzgerald Global Healthcare ConferenceDate: September 19, 2024Time: Fireside Chat at 8:35 a.m. – 9:05 a.m. ETLocation:
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2024, and provided a business update. "We continued to execute well in the second quarter and are encouraged by the early third quarter m
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the U.S. financial markets on Tuesday, August 13, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Tuesday, August 13, 2024Time: 8:30 a.m. Eastern TimeLink: https://register.vevent.com/register/BI59b5706a6c00453a9eed343d4a210de9 To access the conference call, plea
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer. "We are grateful to Adrian for joining Fennec's leadership team at such a critical point in the commercial evolution of the Company last year. His significant experience in evaluating business development opportunities and preparing global commercial operations proved succe
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the "Circular") for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes WithheldDr. Khalid Islam10,100,23896.45%371,2703.54%Mr. Chris A. Rallis9,688,51792.52%782,9917.47%Mr. Marco Brughera9,801,30593.59%670,2036
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Thursday, November 7, 2024Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/e6my278s To access the conference call, please register using https://edge.media-server.com/mmc/p/e6m
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2024, and provided a business update. "We continued to execute well in the second quarter and are encouraged by the early third quarter m
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the U.S. financial markets on Tuesday, August 13, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Tuesday, August 13, 2024Time: 8:30 a.m. Eastern TimeLink: https://register.vevent.com/register/BI59b5706a6c00453a9eed343d4a210de9 To access the conference call, plea
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARK Permanent J-code 07901 Became Effective April 1, 2024 ~ ~ Company Has Approximately $51 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 14, 2024Time:8:30 a.m. Eastern TimeLink:https://register.vevent.com/register/BI137d97d6710341398d6f17d0433dc5b8 To access the conference call, please register using https://register.vevent.com/reg
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and Regulatory Milestones, and Tiered Royalties Up to the Mid-Twenties ~ ~ Pro forma fourth quarter cash in excess of $55 million ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Time:Link: Thursday, March 21, 20248:30 a.m. Eastern Timehttps://register.vevent.com/register/BI02e7eebc14074ab296653cd5d988a0a1 To access the conference call, please register using https://r
~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October 2023 by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for PEDMARQSI ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2023 and provided a business update. "We continued to see strong commercial performance w
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2023 financial results before the opening of the U.S. financial markets on Monday, November 6, 2023. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Monday, November 6, 2023Time: 8:30 a.m. Eastern TimeLink: https://register.vevent.com/register/BId73242c7355a46d19e6aa1ff15435b87 To access the conference call, please register using https://registe
10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
DEF 14A - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
10-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously
CapitalOne initiated coverage of Fennec Pharmaceuticals with a rating of Overweight and set a new price target of $11.00
Craig Hallum resumed coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00
HC Wainwright & Co. reiterated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $15.00 previously
Craig-Hallum initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $17.00
Maxim Group initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.
Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and lowers the price target from $20 to $17.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and lowers the price target from $18 to $15.
Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday's session following mixed first-quarter financial results. The e-commerce giant reported fiscal fourth-quarter 2023 revenue growth of 7% year-on-year to $30.73 billion, beating the analyst consensus estimate of $30.40 billion. Adjusted earnings per ADS of $1.40 missed the analyst consensus estimate of $1.41, according to data from Benzinga Pro. Alibaba Group shares tumbled 6.8% to $78.86 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) shares jumped 352.4% to $5.34 as the company reported pricing of $8.19 million
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.26 by 57.69 percent. This is a 278.26 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $25.377 million which beat the analyst consensus estimate of $18.876 million by 34.44 percent. This is a 1.41K percent increase over sales of $1.677 million the same period last year.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $17 to $18.
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. • InflaRx (NASDAQ:IFRX) is projected to report quarterly loss at $0.20 per share on revenue of $1.42 million. • Fennec Pharmaceuticals (NASDAQ:FENC) is likely to report quarterly loss at $0.02 per share on revenue of $8.67 million. • Welltower (NYSE:WELL) is likely to report quarterly earnings at $0.00 per share on revenue of $218.97 million. • VerifyMe (NASDAQ:VRME) is expected to report quarterly loss at $0.03 per share on revenue of $8.95 million. • Academy Sports (NASDAQ:ASO) is expected to report quarterly earnings at $2.2
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.02) by 400 percent. This is a 61.54 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $9.73 million which beat the analyst consensus estimate of $8.67 million by 12.28 percent. This is a 534.20 percent increase over sales of $1.53 million the same period last year.
Fennec Pharmaceuticals (NASDAQ:FENC) is set to give its latest quarterly earnings report on Thursday, 2024-03-21. Here's what investors need to know before the announcement. Analysts estimate that Fennec Pharmaceuticals will report an earnings per share (EPS) of $-0.02. Fennec Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.04, which was foll